Overview of Brotizolam

What is Brotizolam? Definition and Class

Property	Description
Active ingredient	Brotizolam
Form	Oral Tablet
Pharmacological class	Sedative-Hypnotic
Common purpose	Promoting sleep onset
Origin	Synthetic, Thienotriazolodiazepine

Brotizolam is a synthetic compound classified as a sedative-hypnotic agent belonging to the pharmacological group of benzodiazepine derivatives. Its primary purpose is to quickly aid in the onset of sleep by exerting a pronounced calming effect on the central nervous system. The substance is internationally recognized by the official International Nonproprietary Name (INN), Brotizolam.

Brotizolam is a highly potent hypnotic drug within its class. This medication is specifically categorized as a thienotriazolodiazepine, a structural modification that differentiates it from classic benzodiazepines, defining its characteristically ultra-short-acting profile.

Composition and Form: Understanding its Chemical Origin

The active ingredient is solely Brotizolam, a molecule with the chemical formula C15H10BrClN4S. The drug is a fully synthetic entity, manufactured through controlled chemical processes. It is most commonly supplied as an oral tablet for administration via the oral route.

While Brotizolam is the INN, its consistent single-ingredient formulation across various markets, often known under brand names such as Lendormin, ensures a uniform pharmacological action that is clinically recognized for its reliable potency.

General Purpose and Action Profile

The general purpose of this medication is defined by its action as a central nervous system (CNS) depressant, which reduces overall neurological activity. Its role as a potent sedative-hypnotic means it directly supports the body in achieving a restful state, making it suitable for situations where rapid support is needed to initiate sleep.

A key attribute is its classification as an ultra-short-acting agent. This profile dictates that the drug's potent hypnotic effect is rapid in onset and relatively brief in duration, minimizing the likelihood of prolonged daytime effects. This characteristic rapid clearance is a differentiating factor often cited in its therapeutic use.

What side effects are possible with Brotizolam?

Official Safety Profile and Adverse Reactions

Official regulatory documents classify the possible effects of Brotizolam based on their frequency and the body systems involved. The drug’s safety profile reflects its primary action as a Central Nervous System (CNS) depressant, which necessitates specific safety considerations.

Frequency-Classified Adverse Reactions

Classification	Examples of Documented Effects
Common	Daytime drowsiness, headache, gastrointestinal disturbance.
Uncommon	Dizziness, intense nightmares, aggravation of pre-existing depression.
Rare	Reduced alertness, confusion, fatigue, muscle weakness, anterograde amnesia, visual disorders, hepatic dysfunction.

Serious Adverse Reactions and Safety Constraints

Regulatory labeling specifies clinically significant risks, including the potential for developing physical and psychic dependence, which increases with the dose and duration of use. Abrupt cessation may lead to severe withdrawal symptoms and rebound phenomena, which can, in rare cases, involve epileptic seizures. The risk of anterograde amnesia is explicitly documented, with the severity being dose-dependent.

The drug is contraindicated in individuals with severe hepatic insufficiency and severe respiratory insufficiency. Caution is mandated for co-administration with other CNS depressants, including alcohol, due to the potential for enhanced sedative effects.

Population-Specific Safety Notes

The official safety information addresses specific populations:

Older Adults (Elderly): This group has an increased susceptibility to CNS effects like ataxia (lack of coordination) and confusion, as well as the occurrence of paradoxical reactions (e.g., agitation).
Pregnancy/Neonates: Use late in pregnancy or during labor carries a documented risk of "Floppy Infant Syndrome" in the newborn, characterized by hypotonia and respiratory depression.

The overall safety profile is structured to communicate that the main risks are tied to its potent depressant activity, dependence potential, and specific limitations based on pre-existing health conditions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Brotizolam is primarily characterized by clinical manifestations of Central Nervous System (CNS) depression. Symptoms officially documented in regulatory sources range from mild effects such as drowsiness, confusion, ataxia (lack of coordination), and dysarthria (slurred speech) to more severe clinical signs. Serious outcomes listed include hypotension (low blood pressure) and respiratory depression. In isolated cases, life-threatening toxicity is classified as very low, but the risk for severe outcomes, including coma or death, significantly increases when Brotizolam is co-ingested with other CNS depressants, such as alcohol or opioids.

Immediate medical attention must be sought for signs of severe toxicity, including profound or deepening sedation, or slowed or difficult breathing. Regulator guidance requires referral to a doctor if an accidental dose exceeding the maximum recommended daily amount is taken. Management principles center on clinical observation and supportive care to address symptoms. While the specific antagonist Flumazenil is available, its use is typically reserved for managing the most severe respiratory or cardiovascular complications. Note that official labeling indicates that elderly individuals and very young children are more susceptible to the drug's potent CNS depressant action.

Therapeutic Uses of Brotizolam

What Brotizolam Treats: Main Uses and Benefits

The primary role of this medicine is to offer support during periods of acute or debilitating symptomatic discomfort, mainly focusing on short-term assistance for symptoms related to heightened physiological activity.

Brotizolam is commonly used across conditions presenting with acute episodes, such as those characterized by severe or debilitating sleep-related symptoms. The medicine is relevant in contexts marked by increased discomfort or tension, especially those associated with acute or disruptive episodes, where short-term assistance may help patients cope more steadily with symptom fluctuations.

This medicine is generally applicable when symptoms create noticeable functional strain, often intensifying, and relevant when supportive symptom management is appropriate. It is applied across domains where additional symptomatic support is needed to address symptom clusters that interfere with daily comfort. The therapeutic domains of use include addressing symptoms related to heightened physiological activity, assisting with easing the overall symptom load, and supporting general well-being during symptomatic phases.

Quick Fact: Symptomatic Support

Brotizolam may assist with maintaining functional stability in situations where symptoms lead to temporary functional strain or discomfort.

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Brotizolam

Regulatory authorities classify populations for Brotizolam use into approved, restricted, and contraindicated groups based on official labeling.

Eligibility Scope	Status/Rules (Regulatory Basis)
Populations for whom use is allowed	Adults who do not have documented contraindications are the primary approved population for short-term use.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to brotizolam or other benzodiazepines, severe hepatic insufficiency, severe respiratory insufficiency, sleep apnoea syndrome, and myasthenia gravis.
Age-related eligibility rules	Use is contraindicated in children and adolescents under 18 years of age as safety and efficacy are not established. Use in the elderly (geriatric) population requires extreme caution and a mandatory reduced starting dose.
Pregnancy and lactation eligibility	Use is not recommended during pregnancy or lactation due to insufficient safety data and excretion of the substance into breast milk.
Condition-specific eligibility rules	Patients with rare hereditary metabolic disorders (e.g., galactose intolerance) are contraindicated due to excipient content. Caution is required for patients with a history of dependence or chronic respiratory insufficiency with hypercapnia, which necessitates a dosage reduction.

Connection to the Overall Eligibility Profile

The official eligibility profile is strictly defined by regulatory documents, primarily listing absolute contraindications related to specific severe pre-existing respiratory, hepatic, or muscular conditions. The medicine is reserved for the adult population, with pediatric use prohibited and use restricted in the elderly and individuals with certain high-risk comorbidities.

What should I know about interactions with other medicines?

The official regulatory profile for Brotizolam is structured around two principal interaction patterns: pharmacodynamic potentiation and metabolic clearance modification.

Pharmacodynamic Interactions and Restrictions

Co-administration with Central Nervous System (CNS) depressants, including opioids, anti-psychotics, hypnotics, and sedating antidepressants, leads to a significant potentiation of central nervous effects. This additive pharmacodynamic risk classifies acute intoxication with these substances as a contraindicated combination. The combined use of narcotic analgesics may further enhance psychic dependence.

Pharmacokinetic Interactions (Metabolic Clearance)

Brotizolam is primarily cleared through metabolism mediated by the hepatic enzyme CYP3A4. Agents that inhibit CYP3A4, such as certain azole antifungals (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), reduce drug clearance. This documented interaction increases the medicine's systemic exposure, raising peak plasma concentration (C max) and total AUC. Conversely, CYP enzyme inducers (e.g., Rifampicin) or herbal products like St. John's wort may decrease the overall effect by accelerating metabolism.

Substance and Population Notes

The regulatory profile restricts concurrent intake of Alcohol as it is documented to decrease clearance and enhance perceptions of sedation. Note is made that elderly patients and individuals with impaired liver function have increased sensitivity, heightening the risk associated with additive CNS depressant outcomes. No specific timing separation rules are documented for co-administration.

Mechanism of Action

Brotizolam is a thienotriazolodiazepine that modulates the function of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), within the central nervous system. Its core mechanism involves allosteric binding to the GABA A receptor complex.

Binding to this site enhances the affinity of the receptor for endogenous GABA, which in turn increases the frequency of chloride ion channel opening. This flux of negatively charged chloride ions induces neuronal hyperpolarization, which decreases the resting membrane potential and reduces the neuron's overall capacity to generate an action potential.

This immediate cellular event translates into a cascade effect, leading to a generalized central depressant effect. This action influences neural processes and regulatory circuits in brain regions, including the limbic system and cortex, thereby resulting in a reduction of basal neuronal activity and alterations in the electrophysiological state that governs wakefulness and consciousness.

Dosage and Administration Information

How Brotizolam Is Used

Brotizolam is administered via the oral route as a 0.25 mg tablet, which is typically scored to facilitate flexible dosing at 0.125 mg. The drug is intended for short-term use and should be taken as a single dose once daily.

Administration Timing and Dosing

The medication is typically taken immediately before the intended time of sleep. To optimize absorption, the dose should be taken with a small amount of liquid and generally not on a full stomach. A standard requirement for use is that the user must be able to commit to an uninterrupted sleep period of at least seven to eight hours after taking the tablet.

Dosing Parameter	Standard Protocol
Standard Dose Range	0.125 mg to 0.25 mg per day
Maximum Dose	0.25 mg (not to be exceeded)
Duration Constraint	As short as possible; typically 2 to 4 weeks maximum

Population-Specific Use and Discontinuation

Standard clinical protocols specify dose adjustments for certain populations. For older and debilitated adults, a reduced starting dose, often 0.125 mg, is advised. Dose reduction is also recommended for patients with impaired liver function. The use of this medication is not authorized for the pediatric population (individuals under 18 years of age).

Upon conclusion of the short-term treatment course, discontinuation must be managed by a gradual reduction of the dosage; abrupt cessation is not the procedure described in established clinical protocols.

Recent Clinical Evidence

Evidence for Short-term Sleep Disturbance

Research explored Brotizolam's use in individuals with symptomatic sleep disturbance and included controlled studies. These trials involved adult outpatients who experienced chronic difficulty with falling asleep or staying asleep. Research examined the substance in trials assessing short-term or episodic symptom patterns, primarily over periods of up to three weeks. These studies were structured to compare the substance against either an inactive substance (placebo) or other medications in this class.

Studies monitored Sleep Latency (the time required to fall asleep) and Total Sleep Time (the overall duration of sleep) as key outcomes. Research utilized both objective measures (e.g., Electroencephalography, or EEG) and subjective patient reports. Findings describe patterns observed in the studies, reporting how symptoms changed in the observed populations during the defined short time intervals. Research provides context regarding short-term changes in these sleep parameters.

Research in Hospitalized and Institutionalized Patients

Research examining the use of this substance in more complex patient groups, such as hospitalized adults or institutionalized elderly patients, utilized different types of study designs. The evidence for these groups stems mainly from retrospective analyses and observational cohort studies, which differ from controlled, randomized efficacy trials. These studies were applied in observational settings examining daily-life functioning.

What Remains Uncertain in the Research Landscape

A key limitation in the research is the short-term nature of the primary efficacy data; there is limited information for long-term outcomes and the potential for any changes in the substance's effect over many months. Furthermore, evidence comparing Brotizolam to many newer sleep medications is limited, as much of the foundational data is older. Subgroup findings are uncertain for many specific health conditions or comorbidities, as the results apply only to the relatively healthy adult and elderly populations studied in the controlled settings. The research provides insight into short-term changes, but findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Brotizolam (FAQ)

Q: How quickly should I expect Brotizolam to start working after I take it?

Brotizolam is characterized by rapid absorption and is classified as an ultra-short-acting medication. Official product information states it should be taken immediately before the intended time of sleep to quickly aid in the process of falling asleep.

Q: Is it safe to drink coffee or caffeine while taking Brotizolam?

Official information explicitly warns against combining Brotizolam with alcohol and other Central Nervous System (CNS) depressants because this can increase sedative effects. While caffeine is not specifically listed in all regulatory documents, co-administration of CNS stimulants like caffeine with sedatives is generally approached with caution.

Q: What are the non-sleep-related benefits people sometimes mention about Brotizolam?

Brotizolam’s primary purpose is to induce sleep. However, pharmacology texts indicate it has been associated with effects such as anti-anxiety (anxiolytic), sedative, and muscle relaxant actions, which are common to its pharmacological class.

Q: What is the typical half-life of Brotizolam?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. Official pharmacological data reports that the elimination half-life of Brotizolam is typically short, ranging from 3 to 6 hours, with an average of around 4.4 hours.

Q: Can Brotizolam interact with herbal supplements like St. John's Wort?

Yes, official documentation mentions that Brotizolam is metabolized by the enzyme CYP3A4. Herbal products like St. John's wort (Hypericum perforatum) can act as an enzyme inducer, which may accelerate the metabolism of Brotizolam and potentially decrease its overall effect.

Q: Does Brotizolam have an anxiolytic (anti-anxiety) effect?

As a benzodiazepine derivative, Brotizolam primarily works as a sleep aid, but it also has effects on the central nervous system. Regulatory drug sheets confirm that the depressant effects include both hypnotic (sleep-inducing) and anti-anxiety effects.

Q: Is it better to take Brotizolam right before bed or earlier in the evening?

The medication must be taken immediately before the intended time of sleep, according to official guidelines. This is consistent with the instruction to commit to an uninterrupted sleep period of at least seven to eight hours.

Q: Can Brotizolam be crushed or split to take?

The 0.25 mg tablet is typically scored, which is specifically intended to facilitate administering the lower 0.125 mg dose. General instructions for crushing or manipulation beyond the score line are not detailed in official guidelines.

Q: Can I drive or operate machinery after taking Brotizolam?

Official information advises caution and states that patients should avoid driving or operating dangerous machinery. This is due to the risk that the medication’s effects may carry over to the next morning, potentially causing drowsiness, reduced attention, and decreased reflexes.

Q: Is it normal to feel slightly dizzy when first starting Brotizolam?

Yes, dizziness is a documented side effect when taking Brotizolam. In the official safety profile, dizziness is listed as an uncommon adverse reaction, while the most frequently observed reactions often include drowsiness and headache.

Q: How does Brotizolam help with difficulty falling asleep?

Brotizolam acts in the central nervous system by enhancing the effect of a natural inhibitory chemical called GABA. This process reduces overall neural activity, leading to a calming and generalized depressant effect that helps the user initiate sleep.

Q: What should I do if a side effect of Brotizolam seems very unusual?

Regulatory guidelines emphasize the importance of reporting adverse reactions. If you experience a side effect that seems very unusual or severe, such as confusion or severe agitation, it is advised to seek guidance from a healthcare professional.

Q: Does Brotizolam show up on standard drug tests?

Brotizolam is classified as a benzodiazepine derivative. Due to its classification, compounds of this type are commonly included in drug screening panels.

Q: Are there any known food interactions with Brotizolam?

Regulatory documents recommend taking the dose with a small amount of liquid and generally not on a full stomach to ensure optimal absorption. Some product information leaflets also contain specific warnings against drinking grapefruit juice while undergoing treatment.

Q: Are there any documented cases of paradoxical reactions to Brotizolam?

Yes, paradoxical reactions are documented in the official safety profile. These are reactions that are opposite to the expected effect and may include aggression, agitation, anxiety, or hyperactivity.

Q: Does Brotizolam affect the quality of sleep or just the time it takes to fall asleep?

While Brotizolam is primarily used to decrease the time it takes to fall asleep (sleep latency), research suggests it can influence sleep architecture, potentially increasing certain stages of light sleep while suppressing aspects of deeper sleep stages.

Q: Why do some people experience vivid dreams when taking Brotizolam?

The official safety profile for Brotizolam lists 'intense nightmares' as an uncommon but documented adverse effect. This potential side effect is noted in the official safety profile.

Q: What research supports Brotizolam's effectiveness as a hypnotic?

The effectiveness is supported by controlled clinical studies conducted on adult outpatients experiencing difficulty with sleep. These trials measured key factors like the time it took to fall asleep (Sleep Latency) and the overall duration of sleep (Total Sleep Time) using objective and subjective data.

Q: Can Brotizolam be taken on an empty stomach?

Yes, official regulatory documents state that to optimize the absorption and effect of the medication, it should generally be taken on an empty stomach with a small amount of liquid.

Q: Is Brotizolam ever used for purposes other than sleep (off-label curiosity)?

Its regulatory indication is primarily for insomnia, but in certain markets, official documents also list its approved use as a preanesthetic medication prior to surgery.

Q: What resources are available to learn more about the research on Brotizolam?

The official regulatory documents, such as the Summary of Product Characteristics (SmPC) and official drug labels, contain detailed scientific assessments and references to the clinical evidence that supports the drug’s use.

Q: Is it possible to be allergic to Brotizolam?

Yes, official eligibility criteria state that the medicine is contraindicated, meaning it must not be used, in individuals who are known to have hypersensitivity to Brotizolam or to other medications in the benzodiazepine class.

Q: How common is it to experience rebound insomnia after stopping Brotizolam?

Rebound insomnia, where sleep difficulties return worse than before, is a documented risk upon stopping the medication. The official documentation indicates this risk may increase with higher doses or longer durations of use.

Q: Are there generic versions of Brotizolam available?

The active ingredient, Brotizolam, is available under various trade names (such as Lendormin) but is also marketed under the name 'Brotizolam' followed by the name of the pharmaceutical company, which typically indicates a generic version is available.

How should Brotizolam be stored and disposed of?

Storage Conditions

Official regulatory documents require Brotizolam to be stored away from light, heat, and moisture to maintain its required stability. The medicine must be kept in its original receptacle and the container should be kept tightly closed.

Due to safety concerns, the product is required to be kept out of the reach and sight of children and should be stored locked up, as explicitly stated in labeling.

Disposal Instructions

Any unused or expired Brotizolam must be discarded and not stored after the period of use is complete. Disposal of the contents and container must be carried out according to local and national pharmaceutical waste regulations. The medicine must not be disposed of together with household garbage and must not enter the sewage system, which protects against environmental contamination and misuse.

Brotizolam